Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective Study of IA vs IV Cisplatin in Extremity Osteosarcoma
NCT03909776Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Cisplatin micelle injection (HA132) in osteosarcoma (OS) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Event-free Survival at 5 years and Overall Survival at 5 years. Started Jan 2019; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03909776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909776.